The Digital Therapeutics (DTx) market is expected to grow to USD 14.5 Billion by 2027. Southeast (SE) Asia covers over 670mil people across a range of fast growing markets, and consumers have a high level of digital savviness and acceptance of new technologies. All these factors suggest the region represents a significant opportunity for DTx companies and investors.
This meeting will explore the commercial considerations (i.e market access, demand generation, integration into HCPs workflows and treatment compliance) and opportunities for a DTx product in the SE Asia market. Asia consumers are rapid adopters of healthcare digital technologies, however DTx platforms represent a new area and the paths to market via doctors, insurers, government bodies and other channels also remain to be validated. Another area to discuss will be how these products will engage traditional routes to market vs new channels (i.e: telemedicine). Lastly a bulk of new DTx products are being developed by American and European companies, we will explore the challenges these companies face to bring these technologies to the SE Asia market. Join this meeting to discuss this and more with other thought leaders in the space.